Scrap Citizen Petition Proposal For 505(b)(2), Off-Patent Industry Urges FDA

Citizen Petitions Can ‘Languish Unanswered’ For Years

Several stakeholders across the off-patent industry, including trade groups and manufacturers, have encouraged the FDA to scrap its proposal to require companies to submit citizen petitions for requesting therapeutic equivalence evaluations for 505(b)(2) applications.

Sign outside of FDA's headquarters in White Oak, MD
• Source: Alamy

More from Regulation

More from Policy & Regulation